AIA
BMY.RT

Affinity Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Affinity Investment Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,837
Closed -$9K – 168
2020
Q4 		$9K Sell
12,837
-378
-3% -$805 ﹤0.01% 154
2020
Q3 		$30K Sell
13,215
-111
-0.8% -$317 0.01% 143
2020
Q2 		$48K Sell
13,326
-188
-1% -$678 0.02% 141
2020
Q1 		$51K Buy
13,514
+85
+0.6% +$280 0.03% 134
2019
Q4 		$40K Buy
+13,429
New +$34.9K 0.01% 146

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Affinity Investment Advisors's BMY.RT Position: Q1 2021 in Review

Affinity Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,837 shares — an estimated $9K sold.

Affinity Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $51K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Affinity Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Affinity Investment Advisors sold 12,837 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9K.
  • Affinity Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Affinity Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $51K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Affinity Investment Advisors's 13F filing for Q1 2021, filed 13 May 2021.